Arcturus Reports Positive Preclinical Data for its COVID-19 Vaccine Candidate
April 27, 2020 07:00 ET
|
Arcturus Therapeutics Holdings Inc.
100% of animals seroconverted by day 19 at a low dose (2 µg)LUNAR-COV19 remains on track to initiate human clinical trials this Summer SAN DIEGO, April 27, 2020 (GLOBE NEWSWIRE) -- Arcturus...
Arcturus Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
April 21, 2020 08:00 ET
|
Arcturus Therapeutics Holdings Inc.
SAN DIEGO, April 21, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, NASDAQ: ARCT), a leading clinical-stage messenger RNA medicines company focused on the discovery,...
Arcturus Therapeutics Announces Pricing of $70.0 Million Public Offering of Common Stock
April 16, 2020 09:10 ET
|
Arcturus Therapeutics Holdings Inc.
SAN DIEGO, April 16, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, NASDAQ: ARCT), a leading clinical-stage messenger RNA medicines company focused on the discovery,...
Arcturus Therapeutics Announces Proposed Public Offering of Common Stock
April 15, 2020 16:01 ET
|
Arcturus Therapeutics Holdings Inc.
SAN DIEGO, April 15, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, NASDAQ: ARCT), a leading messenger RNA medicines company focused on the discovery, development and...
Arcturus Therapeutics Announces Allowance of IND & Approval of Clinical Trial Application (CTA) for ARCT-810, a First-in-Class Investigational mRNA Medicine to Treat Ornithine Transcarbamylase Deficiency
April 13, 2020 08:00 ET
|
Arcturus Therapeutics Holdings Inc.
Clinical Plan Includes Healthy Volunteers in New Zealand and OTC-Deficient Patients Across Several Sites in United States Investor Conference Call at 4:00 pm ET Today SAN DIEGO, April 13, 2020 ...
Arcturus Therapeutics Announces Clinical Trial Timeline for its COVID-19 Vaccine
April 09, 2020 07:00 ET
|
Arcturus Therapeutics Holdings Inc.
GMP-Manufactured Batch to be Delivered in June 2020 Human Dosing Expected to Begin in Summer 2020 SAN DIEGO, April 09, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics (the “Company”, NASDAQ:...
Arcturus COVID-19 Vaccine to Benefit from Duke-NUS Genetic Correlation System
March 27, 2020 07:00 ET
|
Arcturus Therapeutics Holdings Inc.
SAN DIEGO, March 27, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics (the “Company”, NASDAQ: ARCT), a leading messenger RNA medicines and vaccines company, today provided details about the Company’s...
Arcturus Therapeutics Reports Fourth Quarter and Year End 2019 Financial Results
March 11, 2020 16:01 ET
|
Arcturus Therapeutics Holdings Inc.
IND Filed for Flagship Program ARCT-810Coronavirus Vaccine Program InitiatedInvestor Conference Call at 4:30 pm ET Today SAN DIEGO, Calif., March 11, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics...
Arcturus Therapeutics and Duke-NUS Medical School Partner to Develop a Coronavirus (COVID-19) Vaccine using STARR Technology™
March 04, 2020 07:30 ET
|
Arcturus Therapeutics Holdings Inc.
SAN DIEGO and SINGAPORE, March 04, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics (the “Company”, NASDAQ: ARCT), a leading messenger RNA medicines company, and Duke-NUS Medical School (Duke-NUS), a...
Arcturus Therapeutics to Report Fourth Quarter and Year-End 2019 Financial Results and Provide Corporate Update on March 11
February 24, 2020 07:30 ET
|
Arcturus Therapeutics Holdings Inc.
SAN DIEGO, Feb. 24, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics (the “Company”, NASDAQ: ARCT), a leading messenger RNA medicines company focused on the discovery, development and...